Filing Flows › Marimed (MRMD) › Q2 2026
Marimed (MRMD) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Marimed (MRMD) reported revenue of $41.9M for the second quarter 2026 (Q2 2026), +6% from a year earlier and +6% from the quarter before. Operating margin was 1.0%, net loss $3.6M (8.5% of revenue).
Marimed, Q2 2026: revenue $41.9M (+6% year over year), operating margin 1.0%, net loss $3.6M, operating cash flow $2.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $41.9M | +6% | +6% |
| Operating profit | $418K | +234% | -63% |
| Net earnings | −$3.6M | — | — |
| Operating cash flow | $2.2M | +134% | +647% |
| Free cash flow | $1.9M | +234% | — |
What changed
Revenue was $41.9M in Q2 2026, up 6% year over year and up 6% from the previous quarter. Product sales - retail was the largest line at 55% of revenue. Product sales - wholesale added $1.4M year over year (up 8%), 57% of the total change.
Gross margin was 38.7%, down 1.6 points from Q2 2025. Operating profit was $418K, a 1.0% margin (down 1.6 points year over year). Operating profit fell $598K even though revenue rose $2.4M versus Q2 2025, so costs grew faster than sales. Operating expenses grew 6% against revenue growth of 6%. The quarter ended with a net loss of $3.6M, narrower than the previous quarter's $3.8M loss. Net interest and other expense of $2.0M was the main reason.
Operating cash flow was $2.2M (up 647% year over year). Non-cash charges added back $2.3M of depreciation and amortization and $350K of share-based compensation. Working capital and other items added $3.1M. Capital expenditures of $298K left free cash flow of $1.9M.
Questions
What was Marimed's revenue in the second quarter 2026?
Marimed (MRMD) reported revenue of $41.9M for the second quarter 2026 (Q2 2026), +6% from a year earlier and +6% from the quarter before.
Was Marimed profitable in the second quarter 2026?
Operating profit was $418K (1.0% of revenue) and net loss $3.6M.
Source: Marimed 10-Q on SEC EDGAR.